ストックスクリーナーアプリを入手
5.6446
4.16%
-0.2454
前日終値:
$5.89
開ける：
$5.76
24時間の取引高:
91,502
Relative Volume:
0.35
時価総額：
$122.82M
収益：
-
当期純損益:
$-57.59M
株価収益率:
-2.1312
EPS:
-2.6486
ネットキャッシュフロー:
$-54.27M
1週間 パフォーマンス:
+3.96%
1か月 パフォーマンス:
+39.73%
6か月 パフォーマンス:
-44.33%
1年 パフォーマンス:
-46.90%
1日の値動き範囲:
$5.37
$5.76
1週間の範囲:
$5.15
$5.93
52週間の値動き範囲:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
名前
Aardvark Therapeutics Inc
セクター
電話
(858) 225-7696
住所
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
5.63 | 128.50M | 0 | -57.59M | -54.27M | -2.6486 |
VRTX
Vertex Pharmaceuticals Inc
|
426.32 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
710.25 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.00 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | ダウングレード | Stifel | Buy → Hold |
| 2026-01-28 | 開始されました | B. Riley Securities | Buy |
| 2025-12-23 | 開始されました | Oppenheimer | Outperform |
| 2025-12-12 | 開始されました | William Blair | Outperform |
| 2025-12-03 | 開始されました | Raymond James | Strong Buy |
| 2025-11-07 | 開始されました | BTIG Research | Buy |
| 2025-09-29 | 開始されました | Stifel | Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 開始されました | BofA Securities | Buy |
| 2025-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 開始されました | Morgan Stanley | Overweight |
| 2025-03-10 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aardvark Therapeutics Inc (AARD) 最新ニュース
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
Number of shareholders of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Aardvark Therapeutics just lost more than half its value - MSN
AARD (Aardvark Therapeutics Inc.) posts narrower Q4 2025 loss than expected, sending shares nearly 5 percent higher.Institutional Grade Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Aardvark Therapeutics Shares Plummet After Trial Halt - Intellectia AI
Repeat: Norsk Hydro: Reminder – Invitation to Hydro’s first quarter results 2026 - Weekly Voice
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - ChartMill
AARD Stock Price and Chart — NASDAQ:AARD - TradingView
Aardvark (AARD) Stock Mega Cap Focus (Trend Weakens) 2026-04-16Expert Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Large Decline in Short Interest - MarketBeat
AARD Technical Analysis & Stock Price Forecast - Intellectia AI
AARD Options Chain — NASDAQ:AARD - TradingView
AARD Options Volatility — NASDAQ:AARD - TradingView
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56% - Intellectia AI
Aardvark Therapeutics Shares Plunge After Trial Halt - Intellectia AI
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Prader-Willi Syndrome Market Size in the 7MM was ~USD 600 million in 2023 and expected to grow by 2034, reveals DelveInsight - Barchart.com
[EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out | NDAQ:AARD | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics (AARD) price target decreased by 43.62% to 18.77 - MSN
Aardvark ups to $150M ATM sale with Piper Sandler (NASDAQ: AARD) - stocktitan.net
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Investors to Connect - ACCESS Newswire
Why Aardvark Therapeutics (AARD) paused late-stage ARD-101 trials after cardiac findings - msn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Insider Monkey
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest - MarketBeat
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
US Stocks Recap: Does Aardvark Therapeutics Inc align with a passive investing strategyWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Heart activity changes prompted pause in trial of ARD-101 in PWS - Prader-Willi Syndrome News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
Aardvark Therapeutics Inc (AARD) 財務データ
収益
当期純利益
現金流量
EPS
Aardvark Therapeutics Inc (AARD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
5.78%
0.81%
大文字化:
|
ボリューム (24 時間):